OBJECTIVE: Lymph node metastasis (LNM) is known to be the most important prognostic factor in cervical cancer. We analyzed the number of positive lymph nodes and other clinicopathological factors as prognostic factors for survival in node-positive patients with cervical cancer. METHODS: Node-positive cervical cancer patients (n = 108) who underwent radical hysterectomy and systematic lymphadenectomy in Hokkaido University Hospital from 1982 to 2002 were enrolled. Clinicopathological data including age, stage, histologic subtype, and the number of LNM sites were collected. The main outcome was the overall survival (OS) rate for Stage Ib-IIb patients treated with surgery and postoperative radiotherapy. RESULTS: The 5-year OS rate of patients with 1 positive node was 93.3%, that for 2 nodes was 77.3%, for 3 nodes it was 33.3%, and for 4 or more it was 13.8%. The OS rate of patients with 1 or 2 LNM sites was significantly better than that for patients with more than 2 LNM sites. The OS rate of patients with adenocarcinoma (Ad) (28.6%) was significantly lower than that for patients with other histologic subtypes (squamous cell carcinoma; 66.7%, adenosquamous carcinoma; 75.0%, p = 0.0003). Multivariate analysis revealed that >2 LNM sites and Ad were independent prognostic factors for survival. The 5-year OS rate of patients with 1 or 2 LNM sites was 86.8%, a more favorable prognosis than the OS rates in other reports. CONCLUSION: More than two LNM sites and adenocarcinoma were independent prognostic factors for node-positive patients with cervical cancer.
OBJECTIVE: Lymph node metastasis (LNM) is known to be the most important prognostic factor in cervical cancer. We analyzed the number of positive lymph nodes and other clinicopathological factors as prognostic factors for survival in node-positive patients with cervical cancer. METHODS: Node-positive cervical cancerpatients (n = 108) who underwent radical hysterectomy and systematic lymphadenectomy in Hokkaido University Hospital from 1982 to 2002 were enrolled. Clinicopathological data including age, stage, histologic subtype, and the number of LNM sites were collected. The main outcome was the overall survival (OS) rate for Stage Ib-IIb patients treated with surgery and postoperative radiotherapy. RESULTS: The 5-year OS rate of patients with 1 positive node was 93.3%, that for 2 nodes was 77.3%, for 3 nodes it was 33.3%, and for 4 or more it was 13.8%. The OS rate of patients with 1 or 2 LNM sites was significantly better than that for patients with more than 2 LNM sites. The OS rate of patients with adenocarcinoma (Ad) (28.6%) was significantly lower than that for patients with other histologic subtypes (squamous cell carcinoma; 66.7%, adenosquamous carcinoma; 75.0%, p = 0.0003). Multivariate analysis revealed that >2 LNM sites and Ad were independent prognostic factors for survival. The 5-year OS rate of patients with 1 or 2 LNM sites was 86.8%, a more favorable prognosis than the OS rates in other reports. CONCLUSION: More than two LNM sites and adenocarcinoma were independent prognostic factors for node-positive patients with cervical cancer.
Authors: W A Peters; P Y Liu; R J Barrett; R J Stock; B J Monk; J S Berek; L Souhami; P Grigsby; W Gordon; D S Alberts Journal: J Clin Oncol Date: 2000-04 Impact factor: 44.544
Authors: Scott E Lentz; Laila I Muderspach; Juan C Felix; Wei Ye; Susan Groshen; Charles A Amezcua Journal: Obstet Gynecol Date: 2004-06 Impact factor: 7.661
Authors: Won Sup Yoon; Dae Sik Yang; Jung Ae Lee; Nam Kwon Lee; Young Je Park; Chul Yong Kim; Nak Woo Lee; Jin Hwa Hong; Jae Kwan Lee; Jae Yun Song Journal: Biomed Res Int Date: 2017-04-27 Impact factor: 3.411
Authors: Jeanny Kwon; Keun-Young Eom; Young Seok Kim; Won Park; Mison Chun; Jihae Lee; Yong Bae Kim; Won Sup Yoon; Jin Hee Kim; Jin Hwa Choi; Sei Kyung Chang; Bae Kwon Jeong; Seok Ho Lee; Jihye Cha Journal: Cancer Res Treat Date: 2017-10-24 Impact factor: 4.679
Authors: Luigi Pedone Anchora; Vittoria Carbone; Valerio Gallotta; Francesco Fanfani; Francesco Cosentino; Luigi Carlo Turco; Camilla Fedele; Nicolò Bizzarri; Giovanni Scambia; Gabriella Ferrandina Journal: Cancers (Basel) Date: 2020-06-12 Impact factor: 6.639